Skip to main content

Table 1 Participant characteristics

From: Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up

 OxytocinPlaceboT valuep value
Number of participants2218  
Age25.00 ± 4.8624.00 ± 5.550.620.54
IQ
 Total IQ102.27 ± 12.45104.61 ± 21.59-0.430.67
 VIQ105.57 ± 9.27108.72 ± 16.83-0.740.47
 PIQ104.76 ± 18.35102.39 ± 22.900.360.72
ADOS(2)
 Total7.18 ± 4.228.06 ± 4.26-0.650.52
 Communication2.05 ± 1.402.39 ± 1.54-0.740.46
 Social interaction4.82 ± 3.505.67 ± 3.33-0.780.44
Use of psychostimulant medication62  
Comorbidity82  
  1. Data are shown as mean ± standard deviation. IQ intelligence quotient, VIQ verbal IQ, PIQ performance IQ, ADOS(2) Autism Diagnostic Observation Schedule(2). Detailed information on medication use and comorbidities is provided in Additional file 1: Table S1. Note that for one participant of the OT group only total IQ information was available, but not VIQ or PIQ, so that the mean (± standard deviation) information of the VIQ and PIQ of the OT group are based on data from 21 participants